Viatris Inc. (VTRS) Institutional Ownership & Insider Trading

1,024 institutions reported holding Viatris Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 3 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

VTRSViatris Inc.Follow VTRS — free

Drug Manufacturers - Specialty & Generic · Healthcare

—

Price chart with a free account

Market cap: 20.7B
P/E TTM: —
Dividend yield: 2.7%
52-week: —
Next earnings: 5 Nov, in 12 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

1,024 institutions held 91.5% of the shares. Across filers that reported both quarters, shares held changed +5.8%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	1,024	1051	+5.8%	310	64	288	72
Mar 26	1,011	990	+1.8%	289	91	266	63
Dec 25	984	975	+0.6%	275	67	274	65
Sep 25	944	964	+0.3%	251	61	295	58
Jun 25	957	975	+0.6%	290	65	320	85
Mar 25	978	958	-2.8%	257	69	322	93
Dec 24	997	994	+3.5%	240	49	339	66
Sep 24	970	942	-4.7%	279	50	298	45

Viatris Inc. — questions

Who owns Viatris Inc. stock?: 1,024 institutions reported Viatris Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: FMR LLC (8.4%), BlackRock, Inc. (7.5%), VANGUARD CAPITAL MANAGEMENT LLC (6.6%).
Are Viatris Inc. insiders buying or selling?: 3 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Viatris Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.